Research Topics
Species | G R LichtensteinSummaryAffiliation: University of Pennsylvania Country: USA Publications
| Collaborators
|
Detail Information
Publications
Importance of mucosal healing in ulcerative colitisGary R Lichtenstein
Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
Inflamm Bowel Dis 16:338-46. 2010..This review evaluates the effect of medical therapy on mucosal healing in patients with UC and explores the importance of this outcome measure, both from the patient's perspective and clinical trial experience. Inflamm Bowel Dis 2009...- MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulationsG R Lichtenstein
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104 4283, USA
Aliment Pharmacol Ther 27:1094-102. 2008..Two phase III studies have evaluated mesalazine (mesalamine) with MMX (Multi Matrix System) technology in patients with active mild-to-moderate ulcerative colitis... - Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behaviorGary R Lichtenstein
Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Inflamm Bowel Dis 17:2488-96. 2011..Previous studies suggest that biomarkers may aid in determining the course of CD. We aimed to determine if combined serologic immune responses and NOD2 genetic markers are associated with CD complications... 
Efficacy and safety of adalimumab in Crohn's diseaseGary R Lichtenstein
University of Pennsylvania School of Medicine Hospital of the University of Pennsylvania, 3rd Floor Ravdin Building 3400 Spruce Street Philadelphia, PA, USA
Therap Adv Gastroenterol 1:43-50. 2008..Based on robust short- and long-term efficacy data from large randomized controlled trials and a favorable safety signal, ADA has become a key addition to the therapeutic armamentarium in the treatment of moderate-to-severe CD...- Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 monthsGary R Lichtenstein
Gastrointestinal Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
Clin Gastroenterol Hepatol 8:600-9. 2010..We assessed the long-term efficacy, safety, and immunogenicity of continuous versus interrupted maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease... - Management of Crohn's disease in adultsGary R Lichtenstein
Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Am J Gastroenterol 104:465-83; quiz 464, 484. 2009..The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time... - Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosaG R Lichtenstein
Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Aliment Pharmacol Ther 28:663-73. 2008..Delayed-release formulations and azo-prodrugs minimize 5-ASA absorption in the upper gastrointestinal (GI) tract... - Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trialsG R Lichtenstein
Gastroenterology Division, Department of Medicine, University of Pennsylvania, Philadelphia, USA
Aliment Pharmacol Ther 36:126-34. 2012..Mesalazine (mesalamine) granules (MG) were shown to be effective for the maintenance of remission of ulcerative colitis (UC) in two double-blind placebo-controlled trials... 
Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's diseaseG R Lichtenstein
Department of Medicine/Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA
Inflamm Bowel Dis 7:S23-9. 2001..This review summarizes the clinical evidence that supports consideration of these agents as alternatives in patients with CD who are dependent on, refractory to, or intolerant of conventional corticosteroid therapy...- Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trialsG R Lichtenstein
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Aliment Pharmacol Ther 30:210-26. 2009..Benefits and risks of concomitant immunomodulators and maintenance infliximab in inflammatory bowel disease (IBD) patients have not been adequately evaluated... - Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysisG R Lichtenstein
Gastroenterology Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
Aliment Pharmacol Ther 29:643-53. 2009..Aim To evaluate budesonide's safety profile in CD patients, in particular, incidences of clinically important AEs known to be associated with systemic GCSs... - Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's diseaseM Pascua
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Aliment Pharmacol Ther 28:545-56. 2008..The use of placebo in randomized clinical trials (PC-RCTs) is often required to evaluate drug efficacy in maintenance of Crohn's disease (CD)... - Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studiesW J Sandborn
Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA
Aliment Pharmacol Ther 34:747-56. 2011..Rapid resolution of symptoms and endoscopic inflammation in ulcerative colitis (UC) represent important treatment goals... - Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphomaJ D Lewis
Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Gastroenterology 118:1018-24. 2000..The objective of this analysis was to determine the impact of azathioprine therapy on survival and quality-adjusted life expectancy after accounting for both the benefits of therapy and potential increased risk of lymphoma... - An approach to the management of refractory ulcerative colitisI Sonu
University of Pennsylvania, School of Medicine, Philadelphia, PA, USA
Minerva Gastroenterol Dietol 56:213-31. 2010..This review focuses on the management and treatment approaches to refractory UC... - Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patientP Pfau
Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA
Am J Gastroenterol 96:895-9. 2001.... - An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitisJ D Lewis
Division of Gastroenterology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104-6021, USA
Am J Gastroenterol 96:3323-8. 2001..CONCLUSIONS: These data suggest that ligands for the gamma subtype of PPARs may represent a novel therapy for ulcerative colitis. A double blind, placebo-controlled, randomized trial is warranted... - Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysisG R Lichtenstein
Gastroenterology Division, Department of Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
Aliment Pharmacol Ther 33:672-8. 2011..Recent studies have focused on the importance of mucosal healing in ulcerative colitis (UC). However, it was still unclear whether higher doses of delayed-release mesalazine (mesalamine) could provide additional benefit... - Review article: Bowel preparation for colonoscopy--the importance of adequate hydrationG R Lichtenstein
Hospital of the University of Pennsylvania, Gastroenterology Division, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
Aliment Pharmacol Ther 26:633-41. 2007..Addressing dehydration-related safety issues through patient screening and education may improve acceptance of bowel preparations, promote compliance and increase the likelihood of a successful procedure... - Clinical trial: sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene glycol solution plus bisacodyl tablets for bowel preparationG R Lichtenstein
University of Pennsylvania, Gastroenterology Division, Philadelphia, PA 19104 4283, USA
Aliment Pharmacol Ther 26:1361-70. 2007..Aim To compare patient acceptance, preference and tolerability of 32-sodium phosphate tablets vs. 2L polyethylene glycol solution plus 4 bisacodyl tablets for bowel preparation... - Treatment of fistulizing Crohn's diseaseG R Lichtenstein
Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
Gastroenterology 119:1132-47. 2000..This review provides an overview of pertinent medical and surgical literature as it pertains to management of patients with fistulizing Crohn's disease... - Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectivesM E Blam
Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA
Am J Gastroenterol 96:1977-97. 2001..The clinical efficacy of these agents and the role of TNF in the pathogenesis of inflammatory bowel disease is reviewed... - Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitisM S Harris
Division of Gastroenterology, Georgetown University School of Medicine, Washington, DC, USA
Aliment Pharmacol Ther 33:996-1009. 2011..The use of topical therapy in the treatment of ulcerative colitis has declined in recent years despite evidence of good efficacy... - Nutrition in inflammatory bowel diseaseR B Stein
University of Pennsylvania School of Medicine, Presbyterian Medical Center, Philadelphia 19104, USA
Curr Opin Clin Nutr Metab Care 2:367-71. 1999..In addition, important advances in the areas of bone disease, vitamin deficiency, growth failure, and home parenteral nutrition will be discussed... - Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trialG R Lichtenstein
Department of Medicine, University of Pennsylvania, Philadelphia, USA
Aliment Pharmacol Ther 32:990-9. 2010..Ulcerative colitis (UC) is a chronic relapsing and remitting idiopathic inflammatory bowel disorder... - Management of bone loss in inflammatory bowel diseaseG R Lichtenstein
Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
Semin Gastrointest Dis 12:275-83. 2001..Assessment of the bone mineral density is an important exercise since new therapeutic options exist and new options are available to combat and even prevent this costly complication... - Review article: monitoring of immunomodulators in inflammatory bowel diseaseF N Aberra
Department of Medicine, Center for Inflammatory Bowel Disease, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, 3400 Spruce Street, 3rd Floor Ravdin Building, Philadelphia, PA 19104-4283, USA
Aliment Pharmacol Ther 21:307-19. 2005..This review provides the latest information for clinicians on efficacy, side-effects, dosing and monitoring of these medications for treatment of inflammatory bowel disease... - Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitisM A Kamm
Department of Medicine, St Vincent s Hospital, Melbourne, Australia
Gut 57:893-902. 2008..2 g/tablet) formulation of 5-aminosalicylic acid. This study evaluated the safety and efficacy of MMX mesalazine dosed once or twice daily as maintenance therapy in patients with ulcerative colitis... - MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trialsW J Sandborn
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
Aliment Pharmacol Ther 26:205-15. 2007..Adverse event frequency was similar in all groups. Conclusion MMX mesalazine is effective and generally well tolerated for inducing clinical and endoscopic remission of active, mild-to-moderate ulcerative colitis... - A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's diseaseB G Feagan
The John P Robarts Research Institute, University of Western Ontario, London, ON, Canada
Aliment Pharmacol Ther 21:373-84. 2005..To evaluate CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for the treatment of corticosteroid-dependent Crohn's disease... - Pediatric Crohn's disease: risk factors for postoperative recurrenceR N Baldassano
Children's Hospital of Philadelphia, Department of Pediatrics, Pennsylvania 19104-4283, USA
Am J Gastroenterol 96:2169-76. 2001..Patients who require preoperative use of 6-MP are likely to suffer from a more aggressive disease and would benefit from postoperative 6-MP prophylaxis. Height growth was improved after intestinal resection for Crohn's disease... - Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remissionW J Sandborn
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
Aliment Pharmacol Ther 26:987-1003. 2007..Patients with Crohn's disease alternate between periods of active, symptomatic disease and periods of remission. The treatment goal for Crohn's disease is to induce and then maintain remission of symptoms...